BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1183 related articles for article (PubMed ID: 15915350)

  • 1. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
    Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
    Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
    Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
    Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
    Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.
    Caballero MD; Rubio V; Rifon J; Heras I; García-Sanz R; Vázquez L; Vidriales B; del Cañizo MC; Corral M; Gonzalez M; León A; Jean-Paul E; Rocha E; Moraleda JM; San Miguel JF
    Bone Marrow Transplant; 1997 Sep; 20(6):451-8. PubMed ID: 9313877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
    Mabed M; Al-Kgodary T
    Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival.
    González-Barca E; Fernández de Sevilla A; Domingo-Claros A; Romagosa V; Martín-Henao GA; De Sanjose S; Carmona M; Petit J; García J; Grañena A
    Bone Marrow Transplant; 2000 Nov; 26(10):1051-6. PubMed ID: 11108302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
    Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
    Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
    Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
    Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience.
    López R; Martino R; Sureda A; Nomdedéu J; Briones J; Martin-Henao G; García J; Brunet S; Sierra J
    Haematologica; 1999 Apr; 84(4):350-5. PubMed ID: 10190950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.